JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

3.6 -3.74

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.6

Max

3.73

Põhinäitajad

By Trading Economics

Sissetulek

-21M

-11M

Müük

-16M

41M

Kasumimarginaal

-27.503

Töötajad

663

EBITDA

-13M

-15M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+53.33% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-18M

475M

Eelmine avamishind

7.34

Eelmine sulgemishind

3.6

Uudiste sentiment

By Acuity

50%

50%

157 / 375 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. juuli 2025, 23:57 UTC

Omandamised, ülevõtmised, äriostud

EQT: To Spend Y407.82B for Tender Offer

29. juuli 2025, 23:56 UTC

Omandamised, ülevõtmised, äriostud

EQT: Tender Offer Price Is Y5,700 a Share

29. juuli 2025, 23:54 UTC

Omandamised, ülevõtmised, äriostud

EQT To Start Tender Offer for Fujitec

29. juuli 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29. juuli 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29. juuli 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29. juuli 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29. juuli 2025, 22:44 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29. juuli 2025, 22:41 UTC

Omandamised, ülevõtmised, äriostud

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29. juuli 2025, 22:41 UTC

Omandamised, ülevõtmised, äriostud

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29. juuli 2025, 22:35 UTC

Tulu

IGO Maintains Nova Life of Mine Production Guidance

29. juuli 2025, 22:35 UTC

Tulu

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29. juuli 2025, 22:35 UTC

Tulu

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29. juuli 2025, 22:34 UTC

Tulu

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29. juuli 2025, 22:34 UTC

Tulu

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29. juuli 2025, 22:34 UTC

Market Talk
Tulu

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29. juuli 2025, 22:33 UTC

Tulu

IGO Had A$279.7 Million of Cash at End-June

29. juuli 2025, 22:33 UTC

Tulu

IGO 4Q Underlying Free Cash A$2.4 Million

29. juuli 2025, 22:33 UTC

Tulu

IGO FY Sales Revenue A$512.5 Million

29. juuli 2025, 22:33 UTC

Tulu

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29. juuli 2025, 22:32 UTC

Tulu

IGO FY Nickel Production 17,173 Tons

29. juuli 2025, 22:32 UTC

Tulu

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29. juuli 2025, 22:32 UTC

Tulu

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29. juuli 2025, 22:31 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

29. juuli 2025, 22:31 UTC

Market Talk
Tulu

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29. juuli 2025, 22:31 UTC

Tulu

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29. juuli 2025, 22:31 UTC

Tulu

IGO FY Spodumene Production 1.48 Million Tons

29. juuli 2025, 22:30 UTC

Tulu

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29. juuli 2025, 22:30 UTC

Tulu

IGO 4Q Underlying Ebitda A$62 Million

29. juuli 2025, 22:22 UTC

Tulu

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

53.33% tõus

12 kuu keskmine prognoos

Keskmine 5.75 USD  53.33%

Kõrge 8 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

2

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

157 / 375 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.